Discovery of AMG 510, a First in Class Oral KRAS G12C Inhibitor
Preclinical evidence and anti-tumour activity in the first dosing cohorts in patients with KRAS G12C mutated cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
EMA Guide on Biosimilars for Healthcare Professionals Available Now in 23 Official EU Languages
The guide is updated in October 2019
Phase I/II Study Results with Lorlatinib in ROS1-positive Advanced NSCLC
Clinical activity observed even in patients with CNS metastases and those previously treated with crizotinib
Women Report More Adverse Drug Reactions Than Men
Higher proportion of serious and fatal adverse drug reactions reported among males
FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer
FDA also approved the Myriad myChoice CDx test for determination of tumour HRD status to select patients for niraparib
EMA Recommends Granting a Marketing Authorisation for Pegfilgrastim Mundipharma
It is a biosimilar of Neulasta which was authorised in the EU in 2002
Rectal Cancer Organoid Platform
Addressing an unmet need to increase ability to study rectal cancer
Number of Deaths, Incident Cases, and Disability-Adjusted Life-Years Caused by Pancreatic Cancer Has More Than Doubled From 1990 To 2017
The increase in incidence of pancreatic cancer is likely to continue as the population ages
EMA Recommends Refusal of the Marketing Authorisation for Quizartinib
It was developed for the treatment of patients with FLT3-ITD positive AML
EMA Recommends Extension of Indications for Daratumumab
New indication concerns its combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
EMA Recommends Extension of Indications for Pembrolizumab
New indication concerns mono or combination with chemotherapy in the first-line treatment of metastatic or unresectable recurrent HNSCC
Social Outcomes after Adolescent and Young Adult Cancer
A programme of research into social outcomes after AYA cancer and its treatment